Coherus BioSciences Inc
Coherus BioSciences is a biopharmaceutical company specialized in developing and commercializing biosimilars
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Coherus BioSciences stock, expecting its price to rise significantly.
Financial Health
Coherus BioSciences is doing well with solid revenue and cash flow, indicating financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CHRS
China's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Biosimilars focus
Coherus targets established biologic markets with lower‑cost alternatives; successful uptake can drive sales, though adoption varies by payer and region.
Commercial traction
Existing launches and partnerships can support revenue growth, but competition and pricing pressure may limit margins and market share.
Regulatory & funding
Approval pathways and reimbursement rules shape prospects; small‑cap balance sheet constraints may require financing, which can dilute holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
